HK1079430A1 - Liquid preparation comprising oligopeptides and etherified cyclodextrin - Google Patents

Liquid preparation comprising oligopeptides and etherified cyclodextrin

Info

Publication number
HK1079430A1
HK1079430A1 HK05111395A HK05111395A HK1079430A1 HK 1079430 A1 HK1079430 A1 HK 1079430A1 HK 05111395 A HK05111395 A HK 05111395A HK 05111395 A HK05111395 A HK 05111395A HK 1079430 A1 HK1079430 A1 HK 1079430A1
Authority
HK
Hong Kong
Prior art keywords
oligopeptides
liquid preparation
etherified cyclodextrin
etherified
cyclodextrin
Prior art date
Application number
HK05111395A
Other languages
English (en)
Inventor
Lindenblatt Hiltrud
Zobel Hans-Peter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1079430A1 publication Critical patent/HK1079430A1/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HK05111395A 2002-06-24 2005-12-12 Liquid preparation comprising oligopeptides and etherified cyclodextrin HK1079430A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10228049A DE10228049A1 (de) 2002-06-24 2002-06-24 Flüssige Zubereitung enthaltend Oligopeptide
PCT/EP2003/005224 WO2004000344A1 (de) 2002-06-24 2003-05-19 Flüssige zubereitung enthaltend oligopeptide und verethertes cyclodextrin

Publications (1)

Publication Number Publication Date
HK1079430A1 true HK1079430A1 (en) 2006-04-07

Family

ID=29723395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111395A HK1079430A1 (en) 2002-06-24 2005-12-12 Liquid preparation comprising oligopeptides and etherified cyclodextrin

Country Status (22)

Country Link
US (1) US7262165B2 (xx)
EP (1) EP1515740B1 (xx)
JP (1) JP5052750B2 (xx)
KR (1) KR101024511B1 (xx)
CN (1) CN100368013C (xx)
AR (1) AR040444A1 (xx)
AT (1) ATE337013T1 (xx)
AU (1) AU2003240268B2 (xx)
BR (1) BR0312157A (xx)
CA (1) CA2490735C (xx)
CY (1) CY1105706T1 (xx)
DE (2) DE10228049A1 (xx)
DK (1) DK1515740T3 (xx)
ES (1) ES2270042T3 (xx)
HK (1) HK1079430A1 (xx)
MX (1) MXPA04012426A (xx)
MY (1) MY135548A (xx)
PL (1) PL205972B1 (xx)
PT (1) PT1515740E (xx)
RU (1) RU2322254C2 (xx)
WO (1) WO2004000344A1 (xx)
ZA (1) ZA200500585B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101090735A (zh) 2004-01-30 2007-12-19 辉瑞产品有限公司 用于使用液体剂型用β－环糊精制备多剂量制剂的抗菌防腐剂
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
BRPI0713080A2 (pt) * 2006-06-29 2012-10-09 Arigen Pharmaceuticals Inc formulação injetável de antibiótico e solução para administração intravenosa da mesma
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
KR20090108713A (ko) * 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
CN101959688B (zh) * 2008-03-01 2013-02-27 惠普开发有限公司 确定载液着色剂浓度的检测设备和方法及lep打印装置
PE20120169A1 (es) * 2008-11-17 2012-02-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
KR20120104316A (ko) 2009-12-10 2012-09-20 메르크 파텐트 게엠베하 올리고펩티드, 바람직하게는 실렌기티드를 포함하는 약학 조성물
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN113197846A (zh) 2013-07-19 2021-08-03 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
AU2014359427B2 (en) 2013-12-04 2017-04-20 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3716948B1 (en) * 2017-11-30 2023-11-22 Cytogel Pharma, LLC Novel analgesic pharmaceutical formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
HUP0201048A3 (en) * 1999-04-15 2002-10-28 Lilly Co Eli Pseudomycin antifungal compositions and their use

Also Published As

Publication number Publication date
RU2005101746A (ru) 2005-08-27
CN1662250A (zh) 2005-08-31
KR101024511B1 (ko) 2011-03-31
AR040444A1 (es) 2005-04-06
PT1515740E (pt) 2007-01-31
MXPA04012426A (es) 2005-04-19
ATE337013T1 (de) 2006-09-15
US20050239692A1 (en) 2005-10-27
BR0312157A (pt) 2005-03-29
JP2005534671A (ja) 2005-11-17
CA2490735C (en) 2012-11-20
DK1515740T3 (da) 2006-12-11
DE10228049A1 (de) 2004-01-15
JP5052750B2 (ja) 2012-10-17
AU2003240268B2 (en) 2008-10-23
EP1515740A1 (de) 2005-03-23
AU2003240268A1 (en) 2004-01-06
RU2322254C2 (ru) 2008-04-20
KR20050013612A (ko) 2005-02-04
CN100368013C (zh) 2008-02-13
DE50304763D1 (de) 2006-10-05
US7262165B2 (en) 2007-08-28
CY1105706T1 (el) 2010-12-22
MY135548A (en) 2008-05-30
ZA200500585B (en) 2005-11-30
EP1515740B1 (de) 2006-08-23
PL372192A1 (en) 2005-07-11
CA2490735A1 (en) 2003-12-31
ES2270042T3 (es) 2007-04-01
PL205972B1 (pl) 2010-06-30
WO2004000344A1 (de) 2003-12-31

Similar Documents

Publication Publication Date Title
HK1079430A1 (en) Liquid preparation comprising oligopeptides and etherified cyclodextrin
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
EP1661818A4 (en) DISCHARGE BODY, DISCHARGE CONTAINER COMPRISING THE DISCHARGE BODY AND INSTILLATION CONTAINER
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL175051A0 (en) Mixtures comprising strobilurins and ethylene modulators
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1616873A4 (en) LIPID REGULATING MEDIUM AND ITS USE
EP1589033A4 (en) ANTIBODY AND ITS USE
AU6268901A (en) Oligopeptides
AU2001262689A1 (en) Oligopeptides
GB0309064D0 (en) Modified peptides and their uses
IL161387A0 (en) Rankl mimics and uses thereof
MY137954A (en) Absorbent structure and absorbent article comprising the absorbent structure
HK1209049A1 (en) Survivin-derived peptides and use thereof
GB2400659B (en) Assay methods and materials
AU2002354567A8 (en) Bcr-Abl oligomerization domain polypeptides and uses therefor
AU2003244927A1 (en) Forestalling long time-outs in processes
SI1515740T1 (sl) Tekoci pripravek, ki vsebuje oligopeptide in zaetreni ciklodekstrin
GB0107628D0 (en) Substances
PL1694845T3 (pl) Przeciwciała przeciwko rakowi i ich zastosowania
GB0115071D0 (en) Substances
GB0017184D0 (en) Container assembly and container unit
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
EP1627888A4 (en) ANTIBODY AND ITS USE
AU2003303464A8 (en) Centrosome-associated protein and applications thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140519